 | • レポートコード：QFJ1-5491 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、129ページ • 納品方法：Eメール（納期：3日） • 産業分類：新技術 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、新型コロナウイルス感染症ワクチンの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（DNA、RNA、その他）、用途別市場規模（軽症患者、重症患者）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・新型コロナウイルス感染症ワクチンの市場動向 ・企業の競争状況、市場シェア ・新型コロナウイルス感染症ワクチンの種類別市場規模と予測2016-2027（DNA、RNA、その他） ・新型コロナウイルス感染症ワクチンの用途別市場規模と予測2016-2027（軽症患者、重症患者） ・新型コロナウイルス感染症ワクチンの北米市場規模2016-2027（アメリカ、カナダ） ・新型コロナウイルス感染症ワクチンの欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・新型コロナウイルス感染症ワクチンのアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・新型コロナウイルス感染症ワクチンの中南米市場規模2016-2027（メキシコ、ブラジル） ・新型コロナウイルス感染症ワクチンの中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Inovio Pharmaceuticals、Takis Biotech (Evvivax)、Zydus Cadila、Codagenix, Inc.、GeoVax, Inc.、Bravovax、Janssen Pharmaceutical Companies、Altimmune、Vaxart、CanSino Biologics、ExpreS2ion Biotechnologies ApS、Clover Biopharmaceuticals、GSK、Vaxil Bio Ltd.、Generex、Novavax, Inc.、Sanofi Pasteur、Baylor、iBio, Inc.、Moderna, Inc.、Curevac、ImmunoPrecise） ・結論 |
In 2021, the global Novel Coronavirus (COVID-19) Vaccine market size will be US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027.
This report focuses on the global Novel Coronavirus (COVID-19) Vaccine status, future forecast, growth opportunity, key market, and key players. The study objectives are to present the Novel Coronavirus (COVID-19) Vaccine development in North America, Europe, Japan, China, Southeast Asia, India, etc.
Global Novel Coronavirus (COVID-19) Vaccine Scope and Market Size
Novel Coronavirus (COVID-19) Vaccine market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Novel Coronavirus (COVID-19) Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
DNA
RNA
Others
Segment by Application
Mild Symptom Patient
Critically Ill Patient
By Region
North America
Europe
Japan
China
Southeast Asia
India
By Company
Inovio Pharmaceuticals
Takis Biotech (Evvivax)
Zydus Cadila
Codagenix, Inc.
GeoVax, Inc.
Bravovax
Janssen Pharmaceutical Companies
Altimmune
Vaxart
CanSino Biologics
ExpreS2ion Biotechnologies ApS
Clover Biopharmaceuticals
GSK
Vaxil Bio Ltd.
Generex
Novavax, Inc.
Sanofi Pasteur
Baylor
iBio, Inc.
Moderna, Inc.
Curevac
ImmunoPrecise
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Type (2021-2027)
1.2.2 DNA
1.2.3 RNA
1.2.4 Others
1.3 Market by Application
1.3.1 Global Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2021-2027)
1.3.2 Mild Symptom Patient
1.3.3 Critically Ill Patient
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size
2.2 Novel Coronavirus (COVID-19) Vaccine Market Size by Regions
2.2.1 Novel Coronavirus (COVID-19) Vaccine Growth Rate by Regions (2021-2027)
2.2.2 Novel Coronavirus (COVID-19) Vaccine Market Share by Regions (2021-2027)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Use Cases
3 Key Players
3.1 Novel Coronavirus (COVID-19) Vaccine Revenue by Players (2020-2021)
3.2 Novel Coronavirus (COVID-19) Vaccine Key Players Headquaters and Area Served
3.3 Key Players Novel Coronavirus (COVID-19) Vaccine Product/Solution/Service
3.4 Date of Enter into Novel Coronavirus (COVID-19) Vaccine Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown by Type and by Application
4.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2021-2027)
4.2 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2021-2027)
5 North America
5.1 North America Novel Coronavirus (COVID-19) Vaccine Market Forecast (2021-2027)
5.2 Novel Coronavirus (COVID-19) Vaccine Key Players in North America
5.3 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Type
5.4 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Application
6.4.4 Canada
6 Europe
6.1 Europe Novel Coronavirus (COVID-19) Vaccine Market Forecast (2021-2027)
6.2 Novel Coronavirus (COVID-19) Vaccine Key Players in Europe
6.3 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Type
6.4 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Application
7 Japan
7.1 Japan Novel Coronavirus (COVID-19) Vaccine Market Forecast (2021-2027)
7.2 Novel Coronavirus (COVID-19) Vaccine Key Players in Europe
7.3 Japan Novel Coronavirus (COVID-19) Vaccine Market Size by Type
7.4 Japan Novel Coronavirus (COVID-19) Vaccine Market Size by Application
8 Rest of World
8.1 China
8.1.1 China Novel Coronavirus (COVID-19) Vaccine Market Analysis
8.1.2 Key Players in China
8.2 Southeast Asia
8.2.1 Southeast Asia Novel Coronavirus (COVID-19) Vaccine Market Analysis
8.2.2 Key Players in Southeast Asia
8.3 India
8.3.1 India Novel Coronavirus (COVID-19) Vaccine Market Analysis
8.3.2 Key Players in India
9 International Player Profiles
9.1 Inovio Pharmaceuticals
9.1.1 Inovio Pharmaceuticals Company Details
9.1.2 Inovio Pharmaceuticals Description and Business Overview
9.1.3 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Introduction
9.1.4 Inovio Pharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
9.1.5 Inovio Pharmaceuticals Recent Development
9.2 Takis Biotech (Evvivax)
9.2.1 Takis Biotech (Evvivax) Company Details
9.2.2 Takis Biotech (Evvivax) Description and Business Overview
9.2.3 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Introduction
9.2.4 Takis Biotech (Evvivax) Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
9.2.5 Takis Biotech (Evvivax) Recent Development
9.3 Zydus Cadila
9.3.1 Zydus Cadila Company Details
9.3.2 Zydus Cadila Description and Business Overview
9.3.3 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Introduction
9.3.4 Zydus Cadila Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
9.3.5 Zydus Cadila Recent Development
9.4 Codagenix, Inc.
9.4.1 Codagenix, Inc. Company Details
9.4.2 Codagenix, Inc. Description and Business Overview
9.4.3 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
9.4.4 Codagenix, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
9.4.5 Codagenix, Inc. Recent Development
9.5 GeoVax, Inc.
9.5.1 GeoVax, Inc. Company Details
9.5.2 GeoVax, Inc. Description and Business Overview
9.5.3 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
9.5.4 GeoVax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
9.5.5 GeoVax, Inc. Recent Development
9.6 Bravovax
9.6.1 Bravovax Company Details
9.6.2 Bravovax Description and Business Overview
9.6.3 Bravovax Novel Coronavirus (COVID-19) Vaccine Introduction
9.6.4 Bravovax Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
9.6.5 Bravovax Recent Development
9.7 Janssen Pharmaceutical Companies
9.7.1 Janssen Pharmaceutical Companies Company Details
9.7.2 Janssen Pharmaceutical Companies Description and Business Overview
9.7.3 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Introduction
9.7.4 Janssen Pharmaceutical Companies Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
9.7.5 Janssen Pharmaceutical Companies Recent Development
9.8 Altimmune
9.8.1 Altimmune Company Details
9.8.2 Altimmune Description and Business Overview
9.8.3 Altimmune Novel Coronavirus (COVID-19) Vaccine Introduction
9.8.4 Altimmune Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
9.8.5 Altimmune Recent Development
9.9 Vaxart
9.9.1 Vaxart Company Details
9.9.2 Vaxart Description and Business Overview
9.9.3 Vaxart Novel Coronavirus (COVID-19) Vaccine Introduction
9.9.4 Vaxart Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
9.9.5 Vaxart Recent Development
9.10 CanSino Biologics
9.10.1 CanSino Biologics Company Details
9.10.2 CanSino Biologics Description and Business Overview
9.10.3 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Introduction
9.10.4 CanSino Biologics Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
9.10.5 CanSino Biologics Recent Development
9.11 ExpreS2ion Biotechnologies ApS
9.11.1 ExpreS2ion Biotechnologies ApS Company Details
9.11.2 ExpreS2ion Biotechnologies ApS Description and Business Overview
9.11.3 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Introduction
9.11.4 ExpreS2ion Biotechnologies ApS Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
9.11.5 ExpreS2ion Biotechnologies ApS Recent Development
9.12 Clover Biopharmaceuticals
9.12.1 Clover Biopharmaceuticals Company Details
9.12.2 Clover Biopharmaceuticals Description and Business Overview
9.12.3 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Introduction
9.12.4 Clover Biopharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
9.12.5 Clover Biopharmaceuticals Recent Development
9.13 GSK
9.13.1 GSK Company Details
9.13.2 GSK Description and Business Overview
9.13.3 GSK Novel Coronavirus (COVID-19) Vaccine Introduction
9.13.4 GSK Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
9.13.5 GSK Recent Development
9.14 Vaxil Bio Ltd.
9.14.1 Vaxil Bio Ltd. Company Details
9.14.2 Vaxil Bio Ltd. Description and Business Overview
9.14.3 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Introduction
9.14.4 Vaxil Bio Ltd. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
9.14.5 Vaxil Bio Ltd. Recent Development
9.15 Generex
9.15.1 Generex Company Details
9.15.2 Generex Description and Business Overview
9.15.3 Generex Novel Coronavirus (COVID-19) Vaccine Introduction
9.15.4 Generex Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
9.15.5 Generex Recent Development
9.16 Novavax, Inc.
9.16.1 Company Details
9.16.2 Novavax, Inc. Description and Business Overview
9.16.3 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
9.16.4 Novavax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
9.16.5 Novavax, Inc. Recent Development
9.17 Sanofi Pasteur
9.17.1 Sanofi Pasteur Company Details
9.17.2 Sanofi Pasteur Description and Business Overview
9.17.3 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Introduction
9.17.4 Sanofi Pasteur Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
9.17.5 Sanofi Pasteur Recent Development
9.18 Baylor
9.18.1 Baylor Company Details
9.18.2 Baylor Description and Business Overview
9.18.3 Baylor Novel Coronavirus (COVID-19) Vaccine Introduction
9.18.4 Baylor Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
9.18.5 Baylor Recent Development
9.18 iBio, Inc.
.1 iBio, Inc. Company Details
.2 iBio, Inc. Description and Business Overview
.3 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
.4 iBio, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
.5 iBio, Inc. Recent Development
9.20 Moderna, Inc.
9.20.1 Moderna, Inc. Company Details
9.20.2 Moderna, Inc. Description and Business Overview
9.20.3 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
9.20.4 Moderna, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
9.20.5 Moderna, Inc. Recent Development
9.21 Curevac
9.21.1 Curevac Company Details
9.21.2 Curevac Description and Business Overview
9.21.3 Curevac Novel Coronavirus (COVID-19) Vaccine Introduction
9.21.4 Curevac Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
9.21.5 Curevac Recent Development
9.22 ImmunoPrecise
9.22.1 ImmunoPrecise Company Details
9.22.2 ImmunoPrecise Description and Business Overview
9.22.3 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Introduction
9.22.4 ImmunoPrecise Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2020-2021)
9.22.5 ImmunoPrecise Recent Development
10 Market Dynamics
10.1 Industry Trends
10.2 Market Drives
10.3 Market Challenges
10.4 Market Restraints
11 Key Findings in This Report
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.2 Data Source
12.2 Disclaimer
12.3 Author Details
Table 1. Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Type (2021-2027) (US$ Million)
Table 2. Key Players of DNA
Table 3. Key Players of RNA
Table 4. Key Players of Others
Table 5. Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth by Application (2021-2027) (US$ Million)
Table 6. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Regions (2021-2027) (US$ Million)
Table 7. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Regions (2021-2027)
Table 8. Market Top Trends
Table 9. Market Use Cases
Table 10. Global Novel Coronavirus (COVID-19) Vaccine Revenue by Players (2020-2021) (US$ Million)
Table 11. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Players (2020-2021)
Table 12. Key Players Headquarters and Area Served
Table 13. Key Players Novel Coronavirus (COVID-19) Vaccine Product Solution and Service
Table 14. Date of Enter into Novel Coronavirus (COVID-19) Vaccine Market
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2021-2027) (US$ Million)
Table 17. Global Novel Coronavirus (COVID-19) Vaccine Market Size Share by Type (2021-2027)
Table 18. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2021-2027) (US$ Million)
Table 19. Global Novel Coronavirus (COVID-19) Vaccine Market Size Share by Application (2021-2027)
Table 20. North America Key Players Novel Coronavirus (COVID-19) Vaccine Revenue (2020-2021) (US$ Million)
Table 21. North America Key Players Novel Coronavirus (COVID-19) Vaccine Market Share (2020-2021)
Table 22. North America Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2021-2027) (US$ Million)
Table 23. North America Novel Coronavirus (COVID-19) Vaccine Market Share by Type (2021-2027)
Table 24. North America Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2021-2027) (US$ Million)
Table 25. North America Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2021-2027)
Table 26. Europe Key Players Novel Coronavirus (COVID-19) Vaccine Revenue (2020-2021) (US$ Million)
Table 27. Europe Key Players Novel Coronavirus (COVID-19) Vaccine Market Share (2020-2021)
Table 28. Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2021-2027) (US$ Million)
Table 29. Europe Novel Coronavirus (COVID-19) Vaccine Market Share by Type (2021-2027)
Table 30. Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2021-2027) (US$ Million)
Table 31. Europe Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2021-2027)
Table 32. Japan Key Players Novel Coronavirus (COVID-19) Vaccine Revenue (2020-2021) (US$ Million)
Table 33. Japan Key Players Novel Coronavirus (COVID-19) Vaccine Market Share (2020-2021)
Table 34. Japan Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2021-2027) (US$ Million)
Table 35. Japan Novel Coronavirus (COVID-19) Vaccine Market Share by Type (2021-2027)
Table 36. Japan Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2021-2027) (US$ Million)
Table 37. Japan Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2021-2027)
Table 38. Key Players in China
Table 39. Key Players in Southeast Asia
Table 40. Key Players in India
Table 41. Inovio Pharmaceuticals Company Details
Table 42. Inovio Pharmaceuticals Description and Business Overview
Table 43. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product
Table 44. Inovio Pharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 45. Inovio Pharmaceuticals Recent Development
Table 46. Takis Biotech (Evvivax) Company Details
Table 47. Takis Biotech (Evvivax) Description and Business Overview
Table 48. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Product
Table 49. Takis Biotech (Evvivax) Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 50. Takis Biotech (Evvivax) Recent Development
Table 51. Zydus Cadila Company Details
Table 52. Zydus Cadila Description and Business Overview
Table 53. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Product
Table 54. Zydus Cadila Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 55. Zydus Cadila Recent Development
Table 56. Codagenix, Inc. Company Details
Table 57. Codagenix, Inc. Description and Business Overview
Table 58. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Product
Table 59. Codagenix, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 60. Codagenix, Inc. Recent Development
Table 61. GeoVax, Inc. Company Details
Table 62. GeoVax, Inc. Description and Business Overview
Table 63. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Product
Table 64. GeoVax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 65. GeoVax, Inc. Recent Development
Table 66. Bravovax Company Details
Table 67. Bravovax Description and Business Overview
Table 68. Bravovax Novel Coronavirus (COVID-19) Vaccine Product
Table 69. Bravovax Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 70. Bravovax Recent Development
Table 71. Janssen Pharmaceutical Companies Company Details
Table 72. Janssen Pharmaceutical Companies Description and Business Overview
Table 73. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Product
Table 74. Janssen Pharmaceutical Companies Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 75. Janssen Pharmaceutical Companies Recent Development
Table 76. Altimmune Company Details
Table 77. Altimmune Description and Business Overview
Table 78. Altimmune Novel Coronavirus (COVID-19) Vaccine Product
Table 79. Altimmune Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 80. Altimmune Recent Development
Table 81. Vaxart Company Details
Table 82. Vaxart Description and Business Overview
Table 83. Vaxart Novel Coronavirus (COVID-19) Vaccine Product
Table 84. Vaxart Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 85. Vaxart Recent Development
Table 86. CanSino Biologics Company Details
Table 87. CanSino Biologics Description and Business Overview
Table 88. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Product
Table 89. CanSino Biologics Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 90. CanSino Biologics Recent Development
Table 91. ExpreS2ion Biotechnologies ApS Company Details
Table 92. ExpreS2ion Biotechnologies ApS Description and Business Overview
Table 93. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Product
Table 94. ExpreS2ion Biotechnologies ApS Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 95. ExpreS2ion Biotechnologies ApS Recent Development
Table 96. Clover Biopharmaceuticals Company Details
Table 97. Clover Biopharmaceuticals Description and Business Overview
Table 98. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product
Table 99. Clover Biopharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 100. Clover Biopharmaceuticals Recent Development
Table 101. GSK Company Details
Table 102. GSK Description and Business Overview
Table 103. GSK Novel Coronavirus (COVID-19) Vaccine Product
Table 104. GSK Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 105. GSK Recent Development
Table 106. Vaxil Bio Ltd. Company Details
Table 107. Vaxil Bio Ltd. Description and Business Overview
Table 108. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Product
Table 109. Vaxil Bio Ltd. Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 110. Vaxil Bio Ltd. Recent Development
Table 111. Generex Company Details
Table 112. Generex Description and Business Overview
Table 113. Generex Novel Coronavirus (COVID-19) Vaccine Product
Table 114. Generex Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 115. Generex Recent Development
Table 116. Novavax, Inc. Company Details
Table 117. Novavax, Inc. Description and Business Overview
Table 118. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Product
Table 119. Novavax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 120. Novavax, Inc. Recent Development
Table 121. Sanofi Pasteur Company Details
Table 122. Sanofi Pasteur Description and Business Overview
Table 123. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Product
Table 124. Sanofi Pasteur Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 125. Sanofi Pasteur Recent Development
Table 126. Baylor Company Details
Table 127. Baylor Description and Business Overview
Table 128. Baylor Novel Coronavirus (COVID-19) Vaccine Product
Table 129. Baylor Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 130. Baylor Recent Development
Table 131. iBio, Inc. Company Details
Table 132. iBio, Inc. Description and Business Overview
Table 133. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Product
Table 134. iBio, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 135. iBio, Inc. Recent Development
Table 136. Moderna, Inc. Company Details
Table 137. Moderna, Inc. Description and Business Overview
Table 138. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Product
Table 139. Moderna, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 140. Moderna, Inc. Recent Development
Table 141. Curevac Company Details
Table 142. Curevac Description and Business Overview
Table 143. Curevac Novel Coronavirus (COVID-19) Vaccine Product
Table 144. Curevac Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 145. Curevac Recent Development
Table 146. ImmunoPrecise Company Details
Table 147. ImmunoPrecise Description and Business Overview
Table 148. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Product
Table 149. ImmunoPrecise Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2020 and 2021
Table 150. ImmunoPrecise Recent Development
Table 151. Novel Coronavirus (COVID-19) Vaccine Market Trends
Table 152. Novel Coronavirus (COVID-19) Vaccine Market Drivers
Table 153. Novel Coronavirus (COVID-19) Vaccine Market Challenges
Table 154. Novel Coronavirus (COVID-19) Vaccine Market Restraints
Table 155. Research Programs/Design for This Report
Table 156. Key Data Information from Secondary Sources
Table 157. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Type in 2021 & 2027
Figure 2. DNA Features
Figure 3. RNA Features
Figure 4. Others Features
Figure 5. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Application in 2021 & 2027
Figure 6. Mild Symptom Patient Case Studies
Figure 7. Critically Ill Patient Case Studies
Figure 8. Novel Coronavirus (COVID-19) Vaccine Report Years Considered
Figure 9. Global Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate (2020-2027) (US$ Million)
Figure 10. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Regions (2020-2027)
Figure 11. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Players in 2021
Figure 12. Global Novel Coronavirus (COVID-19) Vaccine Market Size Market Share by Type (2021-2027)
Figure 13. Global Novel Coronavirus (COVID-19) Vaccine Market Size Market Share by Application (2021-2027)
Figure 14. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application in 2021
Figure 15. North America Novel Coronavirus (COVID-19) Vaccine Market Size 2021-2027 (US$ Million)
Figure 16. Europe Novel Coronavirus (COVID-19) Vaccine Market Size 2021-2027 (US$ Million)
Figure 17. Japan Novel Coronavirus (COVID-19) Vaccine Market Size 2021-2027 (US$ Million)
Figure 18. Novel Coronavirus (COVID-19) Vaccine Market Size in China (2021-2027) (US$ Million)
Figure 19. Novel Coronavirus (COVID-19) Vaccine Market Size in Southeast Asia (2021-2027) (US$ Million)
Figure 20. Novel Coronavirus (COVID-19) Vaccine Market Size in India (2021-2027) (US$ Million)
Figure 21. Bottom-up and Top-down Approaches for This Report
Figure 22. Data Triangulation
Figure 23. Key Executives Interviewed
世界のコロナウイルス用ワクチン市場規模・現状・予測（2021年-2027年） Coronavirus vaccines refer to biological products made from coronaviruses for vaccination. It mainly includes inactivated coronavirus vaccine, live attenuated coronavirus vaccine, coronavirus vaccine based on S protein and so on. In 2021, the global Coronavirus Vaccine market size will be US$ XX mil…- 世界の新型コロナウイルス感染症用中国製医薬品市場規模・現状・予測（2021年-2027年） In 2021, the global Chinese Materia Medica for COVID-19 market size will be US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027. This report focuses on the global Chinese Materia Medica for COVID-19 status, future forecast, growth opportu…
- 世界の新型コロナウイルス感染症治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Covid-19 Treatments Market The global Covid-19 Treatments market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, the report mak…
- 世界の新型コロナウイルス感染症用医薬品市場規模・現状・予測（2021年-2027年） In 2021, the global COVID-19 Drugs market size will be US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027. This report focuses on the global COVID-19 Drugs status, future forecast, growth opportunity, key market, and key players. The stu…
- 世界の新型コロナウイルス感染症特定抗ウイルス薬市場規模・現状・予測（2021年-2027年） In 2021, the global Specific Antiviral Drugs for COVID-19 market size will be US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027. This report focuses on the global Specific Antiviral Drugs for COVID-19 status, future forecast, growth opp…